Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.
JOURNAL OF CLINICAL ONCOLOGY. Bd. 42. H. 3_SUPPL. 2024 S. 290-290
Erscheinungsjahr: 2024
Publikationstyp: Zeitschriftenaufsatz
| Geprüft: | Bibliothek |
Autoren
Cruz-Correa, Marcia (Autor)
Xu, Rui-Hua (Autor)
Moehler, Markus H. (Autor)
Oh, Do-Youn (Autor)
Kato, Ken (Autor)
Spigel, David R. (Autor)
Arkenau, Hendrik-Tobias (Autor)
Tabernero, Josep (Autor)
Zimina, Anastasia V. (Autor)
Bai, Yuxian (Autor)
Shi, Jianhua (Autor)
Lee, Keun-Wook (Autor)
Hirano, Hidekazu (Autor)
Wyrwicz, Lucjan S. (Autor)
Pazo Cid, Roberto (Autor)
Xu, Hui (Autor)
Sheng, Tao (Autor)
Barnes, Gisoo (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
